Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14933663 | 0.96 | SCN9A (0.62) | SCN9ACYP2C9SCN5A | |
| SCHEMBL14921782 | 0.89 | SCN9A (0.52) | SCN9ACYP2C9SCN5A | |
| SCHEMBL16011339 | 0.83 | SCN9A (0.45) | SCN9ACYP2C9SCN5A | |
| SCHEMBL16011331 | 0.82 | SCN9A (0.60) | SCN9ACYP2C9SCN5A | |
| SCHEMBL16021421 | 0.81 | SCN9A (0.53) | SCN9ACYP2C9SCN5A | |
| SCHEMBL14933655 | 0.77 | SCN9A (0.59) | SCN9A | |
| SCHEMBL9923647 | 0.77 | SCN9A (0.51) | SCN9ACYP2C9SCN5A | |
| SCHEMBL16011228 | 0.77 | SCN9A (0.52) | SCN9ACYP2C9SCN5A | |
| SCHEMBL9923645 | 0.76 | SCN9A (0.38) | SCN9A | |
| SCHEMBL16021507 | 0.76 | SCN9A (0.45) | SCN9ACYP2C9SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481677-B2 | Biaryl ether sulfonamides and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-9365578-B2 | — | — | 2016-06-14 | — | — | US | disclosed |
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPV3, TRPV2 | SCN9A 40/4885CYP2C9 304/4885SCN5A 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.